Page last updated: 2024-11-05

methylene chloride

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Methylene Chloride: A chlorinated hydrocarbon that has been used as an inhalation anesthetic and acts as a narcotic in high concentrations. Its primary use is as a solvent in manufacturing and food technology. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

dichloromethane : A member of the class of chloromethanes that is methane in which two of the hydrogens have been replaced by chlorine. A dense, non-flammible colourless liquid at room temperature (b.p. 40degreeC, d = 1.33) which is immiscible with water, it is widely used as a solvent, a paint stripper, and for the removal of caffeine from coffee and tea. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID6344
CHEMBL ID45967
CHEBI ID15767
MeSH IDM0013630

Synonyms (205)

Synonym
AKOS009031498
CHEBI:15767 ,
methylenchlorid
dichlormethan
NCIMECH_000221
metaclen
khladon 30
un1593
ccris 392
rcra waste no. u080
r30 (refrigerant)
nsc 406122
f 30
ai3-01773
chlorure de methylene [french]
un 1593
brn 1730800
rcra waste number u080
hcc 30
metylenu chlorek [polish]
f 30 (chlorocarbon)
hsdb 66
caswell no. 568
soleana vda
methylenum chloratum
einecs 200-838-9
epa pesticide chemical code 042004
inchi=1/ch2cl2/c2-1-3/h1h
methane, dichloro-
solmethine
methane dichloride
aerothene mm
nsc406122
chlorure de methylene
solaesthin
r 30
narkotil
nsc-406122
methylene bichloride
nci-c50102
wln: g1g
freon 30
metylenu chlorek
NCGC00091504-01
C02271
methylene dichloride
75-09-2
dichloromethane
methylene chloride
dichloromethane, for hplc, >=99.9%, contains 40-150 ppm amylene as stabilizer
dichloromethane, purification grade
dichloromethane, analytical standard, stabilized
methylene chloride (nf)
D02330
dichloromethane, acs spectrophotometric grade, >=99.5%, contains 50-150 ppm amylene as stabilizer
dichloride, methylene
chloride, methylene
bichloride, methylene
ch2cl2
dichloromethane, anhydrous, >=99.8%, contains 40-150 ppm amylene as stabilizer
L023970
D0529
D3478
CHEMBL45967
dichloromethane, nf
dichloromethane, acs
M0629
NCGC00260075-01
tox21_202526
dtxsid0020868 ,
dtxcid40868
cas-75-09-2
methylene chloride acs
methylene chloride [nf]
588x2yuy0a ,
4-01-00-00035 (beilstein handbook reference)
dichloromethane [un1593] [poison]
unii-588x2yuy0a
ec 200-838-9
FT-0624717
FT-0624716
methylene chloride [hsdb]
methylene chloride [mi]
methylene chloride [usp-rs]
methylene chloride [vandf]
desflurane impurity e [ep impurity]
dichloromethane [iarc]
methylene chloride [ep monograph]
methylene chloride [fcc]
methylene chloride [ii]
dichloromethane [mart.]
STL264204
methylenechlorid
metylene chloride
methylenchloride
methlene chloride
methylenedichloride
dichlor-methane
dicliloromethane
di-chloromethane
methylene choride
n,n-methylenechloride
mehtylene chloride
methlyenechloride
m.c
dichloromethane-
methylene-chloride
methylenchoride
h2ccl2
methyienechlorid
methyl ene chloride
dichlormethane
dichloro-methane
methylene chlorie
dichlormetane
methyene chloride
methylene,chloride
dicloromethane
methlyene chloride
dichloro methane
dichoromethane
cl2ch2
methylen chloride
dichlorometan
dichloromeihane
mecl2
dichlorometane
methylene cloride
methylenechloride
dichioromethane
dichloro -methane
metylenchloride
methylene di chloride
dichloro- methane
dichlorornethane
dichloromethan
dichlorometliane
J-610006
methoklone
salesthin
mfcd00000881
dichloromethane (peptide grade)
dichloromethane, spectrophotometric grade
dichloromethane, 99%, stab. with ca. 50ppm amylene
dichloromethane, environmental grade
dichloromethane, hplc grade
dichloromethane, anhydrous
methylene chloride hplc grade stabilized with amylene
dichloromethane, selectophore(tm), >=99.5% (gc), inhibitor-free
residual solvent class 2 - methylene chloride, united states pharmacopeia (usp) reference standard
dichloromethane, for hplc
dichloromethane, puriss. p.a., acs reagent, reag. iso, dried, >=99.8% (gc), <=0.001% water
dichloromethane, jis special grade, >=99.0%
dichloromethane, >=99.9%, capillary gc grade, suitable for environmental analysis, contains amylene as stabilizer
dichloromethane, puriss., meets analytical specification of ph.??eur., nf, >=99% (gc)
dichloromethane, analytical standard
dichloromethane, acs reagent, >=99.5%, contains 50 ppm amylene as stabilizer
dichloromethane, acs reagent, >=99.5%, contains 40-150 ppm amylene as stabilizer
dichloromethane, selectophore(tm), >=99.5%
dichloromethane, puriss. p.a., acs reagent, reag. iso, >=99.9% (gc)
dichloromethane, for hplc, >=99.8% (gc)
dichloromethane, biotech. grade, 99.9%, contains 40-150 ppm amylene as stabilizer
dichloromethane, suitable for pcb analysis
dichloromethane, >=99.9%
dichloromethane, saj first grade, >=99.0%
dichloromethane, tlc high-purity grade, >=99.8% (gc)
dichloromethane, laboratory reagent, >=99.9% (without stabilizer, gc), contains 0.1-0.4% ethanol as stabilizer
dichloromethane, for hplc, >=99.8%, contains amylene as stabilizer
dichloromethane, for hplc, >=99.7%
dichloromethane, contains 40-150 ppm amylene as stabilizer, acs reagent, >=99.5%
dichloromethane (methylene chloride)
dichloromethane, anhydrous, contains 40-150 ppm amylene as stabilizer, zero2(tm), >=99.8%
dcm,sp grade
dichloromethane, acs reagent, 99.5%
dichloromethane, special, 99.9%, contains 40-60 ppm amylene
dichloromethane, lr, >=99.5%
dichloromethane, uv hplc spectroscopic, 99.9%, contains 40-60 ppm amylene
dichloromethane, technical grade, 95%, contains 40-60 ppm amylene
methylene chloride, pharmaceutical secondary standard; certified reference material
methylene chloride, european pharmacopoeia (ep) reference standard
dichloromethane, p.a., acs reagent, reag. iso, reag. ph. eur., 99.8%, contains 40-60 ppm amylene
dichloromethane, ar, >=99%
dichloromethane hplc, uv/ir, min. 99.8%, isocratic grade
dichloromethane 1000 microg/ml in methanol
dichloromethane 100 microg/ml in methanol
methylene chloride; dichloromethane; dcm
distillex ds3
m-clean d
driverit
nevolin
aerothene
dichloromethane, glass distilled hrgc/hplc trace grade
Q421748
Q425210
chlorodorm d
DTXSID60166893
dichloromethane, 99%, stabilized with ethanol
dichloromethane (mart.)
methylene chloride (ep monograph)
dichloromethane; methylene chloride
methylene chloride (ii)
r 30 (refrigerant)
dichloromethane (iarc)
dichloromethane (dot:osha)
SY010434

Research Excerpts

Overview

Methylene chloride is a halogenated organic solvent widely used in paint strippers, cleaners, adhesives, and sealants. It is a chlorinated hydrocarbon used widely in home and industry.

ExcerptReferenceRelevance
"Methylene chloride is a halogenated organic solvent widely used in paint strippers, cleaners, adhesives, and sealants. "( Assessment of Methylene Chloride-Related Fatalities in the United States, 1980-2018.
Cannon, DL; Fagan, K; Harrison, R; Hoang, A; Rayasam, SDG; Shusterman, D; Singla, V, 2021
)
2.42
"Methylene chloride is an industrial solvent used in commercial paint strippers and degreasing agents. "( Methylene Chloride.
Phillips, JA, 2018
)
3.37
"Methylene chloride is a high production chemical used in a variety of applications resulting in estimated occupational and consumer exposures of at least one million people per day. "( Effect of varying exposure regimens on methylene chloride-induced lung and liver tumors in female B6C3F1 mice.
Anderson, MW; Foley, JF; Kari, FW; Maronpot, RR; Seilkop, SK, 1993
)
2
"Methylene chloride is a major component of paint and varnish strippers. "( Fatal gassing due to methylene chloride - a case report.
Sam, CT; Tan, KT; Tay, P, 1995
)
2.05
"Methylene chloride is a solvent used in domestic and industrial preparations, such as paint removers and degreasing agents. "( Diverse manifestations of oral methylene chloride poisoning: report of 6 cases.
Chang, YL; Deng, JF; Ger, J; Liaw, HC; Liaw, SJ; Tsai, WJ; Wu, ML; Yang, CC, 1999
)
2.03
"Methylene chloride is an organic solvent with many industrial uses. "( Treatment of methylene chloride induced carbon monoxide poisoning with hyperbaric oxygenation.
Rudge, FW, 1990
)
2.09
"Methylene chloride is a chlorinated hydrocarbon used widely in home and industry. "( Methylene chloride inhalation: an unusual form of drug abuse.
Caraccio, T; Mofenson, H; Sturmann, K, 1985
)
3.15

Effects

Methylene chloride has been shown to be a lung and liver carcinogen in the mouse. The current epidemiologic data show no adverse health effects associated with chronic exposure to this compound.

ExcerptReferenceRelevance
"Methylene chloride has had wide use in industry although it has been identified as potentially hazardous to exposed workers and the environment."( Results of the Massachusetts methylene chloride end-users survey.
Ellenbecker, MJ; Roelofs, CR, 2003
)
1.33
"Methylene chloride has been the subject of recent toxicological and carcinogenesis studies because of significant human exposure and widespread use in industrial processing, food preparation and agriculture. "( Ras proto-oncogene activation in liver and lung tumors from B6C3F1 mice exposed chronically to methylene chloride.
Anderson, MW; Devereux, TR; Foley, JF; Kari, F; Maronpot, RR, 1993
)
1.95
"Methylene chloride has been shown to be a lung and liver carcinogen in the mouse; yet, the current epidemiologic data show no adverse health effects associated with chronic exposure to this compound. "( Comparison of the cancer risk of methylene chloride predicted from animal bioassay data with the epidemiologic evidence.
Brown, RN; Lorentzen, RJ; Springer, JA; Tollefson, L, 1990
)
2
"Methylene chloride (MC) has been evaluated for its ability to induce micronucleated polychromatic erythrocytes (MPEs) in the bone marrow of treated mice. "( Inactivity of methylene chloride in the mouse bone marrow micronucleus assay.
Elliott, BM; Richardson, CR; Sheldon, T, 1987
)
2.08

Treatment

Methylene chloride treated specimens were significantly higher than those of completely desiccated specimens. Treated methylene chloride provided acceptable ETU recoveries for up to 1 month after "purification"

ExcerptReferenceRelevance
"For methylene chloride treated specimens, bond strengths of both repair and reline resins to completely water saturated specimens were significantly higher than those of completely desiccated specimens (P = .0048 for repair resin, P < .0001 for reline resin) after thermal cycling."( In vitro evaluation of the influence of repairing condition of denture base resin on the bonding of autopolymerizing resins.
Kurashige, H; Minami, H; Minesaki, Y; Suzuki, S; Tanaka, T, 2004
)
0.8
"Treated methylene chloride provided acceptable ETU recoveries for up to 1 month after "purification.""( Determination of methylene chloride acceptability and its "purification" for ethylenethiourea methodology.
Kendall, DC; Krause, RT; Sack, CA,
)
0.87

Toxicity

ExcerptReferenceRelevance
" During rodent chronic toxicity studies metabolism may vary according to the age of the animal, or as a result of the effect of the chemical on its own metabolism, or as a result of the toxic properties of the chemical."( Changes in metabolism during toxicity tests.
Green, T, 1990
)
0.28
" To demonstrate the technique, the variability of safe dose estimates for exposure to methylene chloride is considered."( Variability of safe dose estimates when using complicated models of the carcinogenic process. A case study: methylene chloride.
Kaplan, NL; Portier, CJ, 1989
)
0.71
" These results suggest that the exposure limit for a chemical with a short biological half-life and readily reversible toxic effect may not need to be adjusted for a longer workshift which is in agreement with some of the mathematical models based upon the pharmacokinetics of a toxicant."( The effect of an unusual workshift on chemical toxicity. I. Studies on the exposure of rats and mice to dichloromethane.
Carlson, GP; Kim, YC, 1986
)
0.27
" The lowest toxic effect levels after 90 days of treatment were found to be approximately 190 and 580 mg/kg for rats and mice, respectively."( Review of investigations of dichloromethane metabolism and subchronic oral toxicity as the basis for the design of chronic oral studies in rats and mice.
Brown, NM; Coots, RH; Kirschman, JC; Morgareidge, K, 1986
)
0.27
"The toxic effects of dichloromethane (DCM) are reviewed."( Safety standards for occupational exposure to dichloromethane.
Babish, JG; Skrabalak, DS, 1983
)
0.27
" The marked differences in substrate affinity of rat and bacterial DCM-active GST, as well as in the toxicity and genotoxicity associated with expression of these enzymes in bacteria, suggest that bacterial DCM dehalogenases/GST have evolved to minimise the toxic effects associated with glutathione-mediated catalysis of DCM conversion."( Enzyme-mediated dichloromethane toxicity and mutagenicity of bacterial and mammalian dichloromethane-active glutathione S-transferases.
Gisi, D; Leisinger, T; Vuilleumier, S, 1999
)
0.3
" VE and VC, at proper concentrations, can reduce or eliminate the adverse effects derived from high doses of DEV."( In vitro study on the genotoxicity of dichloromethane extracts of valerian (DEV) in human endothelial ECV304 cells and the effect of vitamins E and C in attenuating the DEV-induced DNA damages.
Dong-fang, Z; Hui-lian, W; Qian-rong, Li; Yang, L; Yu-zhen, W; Zhao-feng, L, 2003
)
0.32
" Comparison of EC(50) data obtained with the two methods shows that in both cases 3,5-dichlorophenol is more toxic than other compounds investigated and dichloromethane has a very low toxicity value."( Toxicity assessment of common xenobiotic compounds on municipal activated sludge: comparison between respirometry and Microtox.
Laera, G; Ramadori, R; Ricco, G; Tomei, MC, 2004
)
0.32
" It is highly likely that critical, limiting steps in any given mechanistic pathway may become overwhelmed with increasing exposures, signaling the emergence of new modalities of toxic tissue injury at these higher doses."( Dose-dependent transitions in mechanisms of toxicity: case studies.
Andersen, ME; Bogdanffy, MS; Bus, JS; Cohen, SD; Conolly, RB; David, RM; Doerrer, NG; Dorman, DC; Gaylor, DW; Hattis, D; Rogers, JM; Setzer, RW; Slikker, W; Swenberg, JA; Wallace, K, 2004
)
0.32
"The toxic effects of the extracts of Allium sativum (Garlic) were evaluated against adults of Hyalomma marginatum rufipes and Rhipicephalus pulchellus using three types (Types A, B and C) of contact toxicity bioassays."( In vitro investigation of the toxic effects of extracts of Allium sativum bulbs on adults of Hyalomma marginatum rufipes and Rhipicephalus pulchellus.
Eloff, JN; Magano, SR; Nchu, F, 2005
)
0.33
" The present study evaluated the toxic effects of dichloromethane (DcM) extract of Kielmeyera coriacea stems, administered to rodents."( Preliminary toxicity study of dichloromethane extract of Kielmeyera coriacea stems in mice and rats.
Audi, EA; da Silva Sela, VR; da Silva, JC; Garcia Cortez, DA; Ishida, K; Nakamura, CV; Obici, S; Otobone, FJ, 2008
)
0.35
"The acute toxic and biochemical effects of dichloromethane and 1,2-dichloroethane to Chlorella pyrenoidosa were assessed."( [Toxic effects of dichloromethane and dichloroethane to Chlorella pyrenoidosa].
Chen, JM; Wu, EM; Wu, SJ; Yu, X, 2010
)
0.36

Pharmacokinetics

The carcinogenicity of methylene chloride (DCM) is related to target organ metabolism of DCM by glutathione S-transferase (GST) The permeability constants for DCM and other dihalomethanes were calculated using a pharmacokinetic model.

ExcerptReferenceRelevance
"Gastrointestinal (GI) absorption in physiologically based pharmacokinetic models is typically described as first-order transfer from one compartment directly into the liver."( Gastrointestinal absorption of xenobiotics in physiologically based pharmacokinetic models. A two-compartment description.
Connolly, RB; Fisher, JW; Staats, DA,
)
0.13
" Physiologically based pharmacokinetic models are accurate tools for taking these non-linearities into account."( Physiologically-based pharmacokinetic models in risk and exposure assessment.
Blancato, JN, 1991
)
0.28
" We have developed a physiologically based pharmacokinetic (PB-PK) model which describes the kinetics of CO, carboxyhemoglobin (HbCO), and parent dihalomethane, and have applied this model to examine the inhalation kinetics of CO and of DCM in rats and humans."( Physiologically based pharmacokinetic modeling with dichloromethane, its metabolite, carbon monoxide, and blood carboxyhemoglobin in rats and humans.
Andersen, ME; Clewell, HJ; Gargas, ML; MacNaughton, MG; McKenna, MJ; Nolan, RJ; Reitz, RH, 1991
)
0.28
"The present study evaluates the sensitivity of pharmacokinetic model output to variability in the biochemical and metabolic input parameters."( Sensitivity analysis for physiologically based pharmacokinetic models.
Hetrick, DM; Jarabek, AM; Travis, CC, 1991
)
0.28
"Physiologically based pharmacokinetic (PB-PK) models describe the dynamic behavior of chemicals and their metabolites in individual tissues of living animals."( In vitro metabolism of methylene chloride in human and animal tissues: use in physiologically based pharmacokinetic models.
Guengerich, FP; Mendrala, AL; Reitz, RH, 1989
)
0.59
" No observable pharmacokinetic or metabolic effect resulted from repeated oral dosing over the 2-wk treatment period."( The pharmacokinetics of dichloromethane. I. Disposition in B6C3F1 mice following intravenous and oral administration.
Angelo, MJ; Hawkins, DR; Pritchard, AB; Roberts, A; Waller, AR, 1986
)
0.27
" No observable pharmacokinetic or metabolic effect resulted from repeated oral dosing."( The pharmacokinetics of dichloromethane. II. Disposition in Fischer 344 rats following intravenous and oral administration.
Angelo, MJ; Hawkins, DR; Pritchard, AB; Roberts, A; Waller, AR, 1986
)
0.27
"Physiologically-based pharmacokinetic (PB-PK) models provide a mechanism for reducing the uncertainty inherent in extrapolating the results of animal toxicity tests to man."( Incorporation of in vitro enzyme data into the physiologically-based pharmacokinetic (PB-PK) model for methylene chloride: implications for risk assessment.
Andersen, ME; Guengerich, FP; Mendrala, AL; Park, CN; Reitz, RH, 1988
)
0.49
" This paper advocates use of a physiologically-based pharmacokinetic (PB-PK) model for determining adjustment factors for unusual exposure schedules, an approach that should be more accurate than those proposed previously."( Adjusting exposure limits for long and short exposure periods using a physiological pharmacokinetic model.
Andersen, ME; Clewell, HJ; MacNaughton, MG; Paustenbach, DJ, 1987
)
0.27
" First, permeability constants for dibromomethane (DBM), bromochloromethane (BCM), and methylene chloride (DCM) were calculated by using a physiologically based pharmacokinetic model for dihalomethanes to relate blood concentrations during dermal vapor exposures to the total amount of chemical which was absorbed through the skin."( A physiological pharmacokinetic model for dermal absorption of vapors in the rat.
Andersen, ME; Clewell, HJ; Jepson, GW; MacNaughton, MG; McDougal, JN, 1986
)
0.49
" A physiologically based pharmacokinetic (PB-PK) model based on knowledge of these pathways was used to describe the metabolism of DCM in four mammalian species (mouse, rat, hamster, and humans)."( Physiologically based pharmacokinetics and the risk assessment process for methylene chloride.
Andersen, ME; Clewell, HJ; Gargas, ML; Reitz, RH; Smith, FA, 1987
)
0.5
" Subsequently, the model was expanded to simulate pharmacokinetic behavior in mice and rats following single and repeated oral exposures."( Simulations of methylene chloride pharmacokinetics using a physiologically based model.
Angelo, MJ; Pritchard, AB, 1984
)
0.62
" Very few differences, apart from the change in the nature of the pharmacokinetic model, were seen in the rate coefficients over the dose range tested."( Chlorinated aliphatic hydrocarbons used in the foods industry: the comparative pharmacokinetics of methylene chloride, 1,2 dichloroethane, chloroform and trichloroethylene after I.V. administration in the rat.
Collins, BT; Withey, JR,
)
0.35
" In physiologically based pharmacokinetic (PBPK) models, compartments correspond more closely to actual anatomical structures, defined with respect to their volumes, blood flows, chemical binding (partitioning) characteristics, and ability to metabolize or excrete the compounds of interest."( Development of physiologically based pharmacokinetic and physiologically based pharmacodynamic models for applications in toxicology and risk assessment.
Andersen, ME, 1995
)
0.29
"The parameters in a physiologically based pharmacokinetic (PBPK) model of methylene chloride were varied systematically, and the resulting variation in a number of model outputs was determined as a function of time for mice and humans at several exposure concentrations."( Sensitivity of physiologically based pharmacokinetic models to variation in model parameters: methylene chloride.
Carpenter, RL; Clewell, HJ; Lee, TS, 1994
)
0.74
" have developed physiologically based pharmacokinetic models for the human metabolism of methylene chloride (dichloromethane; DCM) and have advanced the hypothesis that the carcinogenicity of DCM is related to target organ metabolism of DCM by glutathione S-transferase (GST)."( The impact of exercise and intersubject variability on dose estimates for dichloromethane derived from a physiologically based pharmacokinetic model.
Bailer, AJ; Dankovic, DA, 1994
)
0.51
"Physiologically based pharmacokinetic (PBPK) modeling involves mathematically describing the complex interplay of the critical physicochemical and biological determinants involved in the disposition of chemicals."( Physiologically based pharmacokinetics and cancer risk assessment.
Andersen, ME; Krishnan, K, 1994
)
0.29
"The objective of this study was to develop an approach for incorporating tissue composition data into physiologically based pharmacokinetic (PBPK) models in order to facilitate "built-in" calculation of tissue: air partition coefficients (PCs) of volatile organic chemicals."( An approach for incorporating tissue composition data into physiologically based pharmacokinetic models.
Krishnan, K; Pelekis, M; Poulin, P,
)
0.13
"The objective of this study was to develop an index that would provide a quantitative measure of the degree of discrepancy between simulations of physiologically based pharmacokinetic (PBPK) models and experimental data."( A simple index for representing the discrepancy between simulations of physiological pharmacokinetic models and experimental data.
Haddad, S; Krishnan, K; Pelekis, M,
)
0.13
" The studies reported here attempt to continue in the spirit of the new RfC guidelines by incorporating both mechanistic and delivered dose information using a physiologically based pharmacokinetic (PBPK) model, along with quantitative dose-response information using the benchmark dose (BMD) method, into the noncancer risk assessment paradigm."( Investigation of the potential impact of benchmark dose and pharmacokinetic modeling in noncancer risk assessment.
Clewell, HJ; Gearhart, JM; Gentry, PR, 1997
)
0.3
" Pharmacokinetic application with intravenous tramadol in humans and rabbits revealed that tramadol followed a two-compartment open model with one distribution phase and one elimination phase."( Determination of tramadol by capillary gas chromatography with flame ionization detection. Application to human and rabbit pharmacokinetic studies.
Ho, CM; Ho, ST; Li, JH; Liaw, WJ; Wan, JJ, 1999
)
0.3
"Modeling of pharmacokinetic parameters and pharmacodynamic actions requires knowledge of the arterial blood concentration."( Physiologically based pharmacokinetic modeling of arterial - antecubital vein concentration difference.
Levitt, DG, 2004
)
0.32
"A physiologically based pharmacokinetic (PBPK) model for the tissues drained by the antecubital vein (referred to as "arm") is developed."( Physiologically based pharmacokinetic modeling of arterial - antecubital vein concentration difference.
Levitt, DG, 2004
)
0.32
" The objective of this study was to identify age- and gender-specific differences in physiological and biochemical processes that affect tissue dosimetry and integrate them into a predictive physiologically based pharmacokinetic (PBPK) life-stage model."( Evaluation of the potential impact of age- and gender-specific pharmacokinetic differences on tissue dosimetry.
Clewell, HJ; Covington, TR; Gentry, PR; Sarangapani, R; Teeguarden, JG, 2004
)
0.32
" Physiologically based pharmacokinetic modeling was considered to be the appropriate tool to address all these topics in an adequate way."( Application of physiologically based pharmacokinetic modeling in setting acute exposure guideline levels for methylene chloride.
Bos, PM; van Eijkeren, JC; Zeilmaker, MJ, 2006
)
0.55
"A rapid and sensitive liquid chromatography-tandem mass spectrometric method (LC-MS/MS) for the determination of bromotetrandrine in rat plasma has been developed and applied to pharmacokinetic study in Sprague-Dawley (SD) rats after a single oral administration."( Liquid chromatographic/mass spectrometry assay of bromotetrandrine in rat plasma and its application to pharmacokinetic study.
Li, Q; Liu, C; Song, N; Zhang, S, 2009
)
0.35
" Physiologically based pharmacokinetic (PBPK) models are useful tools for calculation of internal and target organ doses of parent compound and metabolites."( Evaluation of two different metabolic hypotheses for dichloromethane toxicity using physiologically based pharmacokinetic modeling for in vivo inhalation gas uptake data exposure in female B6C3F1 mice.
Caldwell, JC; Evans, MV, 2010
)
0.36
" This chromatographic procedure was then applied to the in vivo pharmacokinetic studies in rats for determining the advantages of intranasal administration of the drug over oral administration."( Rapid and sensitive determination of udenafil in plasma by LC-MS/MS for intranasal pharmacokinetic study in rats.
Cha, BJ; Cho, HJ; Chung, SJ; Kang, SK; Kim, DD; Kim, JH; Kim, JS; Kim, KM; Ku, WS; Shim, CK; Yoon, IS, 2011
)
0.37
"Physiologically based pharmacokinetic (PBPK) models may be useful in emergency risk assessment, after acute exposure to chemicals, such as dichloromethane (DCM)."( Evaluation of three physiologically based pharmacokinetic (PBPK) modeling tools for emergency risk assessment after acute dichloromethane exposure.
Bessems, JG; Boerleider, RZ; Bos, PM; de Vries, I; Hof, BG; Hunault, CC; Meulenbelt, J; Olie, JD; van Eijkeren, JC, 2015
)
0.42
" Thymopentin is widely used in the clinic and represents a promising target for drug design but bioanalytical and pharmacokinetic data are limited due to its enzymatic instability."( Determination of thymopentin in beagle dog blood by liquid chromatography with tandem mass spectrometry and its application to a preclinical pharmacokinetic study.
Cai, L; Fang, C; Fawcett, JP; Gao, Y; Gu, J; Shi, M; Sun, H; Sun, Y; Wang, C; Yang, Y; Zhou, X, 2015
)
0.42
" Physiologically based pharmacokinetic models for adults (AD), neonates (NEO), toddlers (TODD), and pregnant women (PW) were used to simulate inhalation exposure to "low" (RfC-like) or "high" (AEGL-like) air concentrations of benzene (Bz) or dichloromethane (DCM), along with various levels of toluene alone or toluene with ethylbenzene and xylene."( Assessing human variability in kinetics for exposures to multiple environmental chemicals: a physiologically based pharmacokinetic modeling case study with dichloromethane, benzene, toluene, ethylbenzene, and m-xylene.
Haddad, S; Valcke, M, 2015
)
0.42

Compound-Compound Interactions

ExcerptReferenceRelevance
"In this paper, a high-performance thin-layer chromatography (HPTLC) method combined with densitometry has been described."( Quantitative analysis of phenobarbital in dosage form by thin-layer chromatography combined with densitometry.
Kryska, M; Matysik, G; Skalska, A; Wójciak-Kosior, M,
)
0.13

Bioavailability

ExcerptReferenceRelevance
" Cl2MDP is poorly absorbed with an absolute bioavailability of only 1% to 2%."( Clodronate kinetics and bioavailability.
Ampulski, RS; Benedict, JJ; Floyd, BF; Poynor, WJ; Slough, CL; Talbert, RL; Yakatan, GJ, 1982
)
0.26
" The improvement of its bioavailability would be beneficial for the treatment of the disorders caused by its homozygous deficiency or by an other plasmatic inhibitor deficiency."( Identification of protein C epitopes altered during its nanoencapsulation.
Aiach, M; Bonneaux, F; Chognot, D; Gaussem, P; Pittet, JL; Vigneron, C; Zambaux, MF, 1999
)
0.3
" The in vivo oral absorption study in dogs showed that bioavailability of tacrolimus from SDF with HPMC was remarkably improved compared with the crystalline powder."( Establishment of new preparation method for solid dispersion formulation of tacrolimus.
Higaki, K; Ibuki, R; Kimura, T; Nakate, T; Ohike, A; Okimoto, K; Tokunaga, Y; Yamashita, K, 2003
)
0.32
"The objective of the present study is to develop microspheres for celecoxib to enhance its bioavailability by increasing its gastric residence time."( Development and evaluation of a gastroretentive drug delivery system for the low-absorption-window drug celecoxib.
Ahuja, A; Ali, J; Baboota, S; Hasan, S; Tyagi, P,
)
0.13
" The cationic charge (due to the presence of chitosan) of these particles is expected to favour oral absorption and thus overall bioavailability of orally administered amifostine."( Preparation of polylactide-co-glycolide and chitosan hybrid microcapsules of amifostine using coaxial ultrasonic atomizer with solvent evaporation.
Bostanian, LA; Graves, RA; Kishore, V; Mandal, TK; Moiseyev, R; Pamujula, S, 2008
)
0.35
"5) and 30% (w/w) MPT had a low relative bioavailability compared with the commercial product Lopressor®, which significantly improved at higher MPT concentration (50%, w/w)."( Sustained-release and swelling characteristics of xanthan gum/ethylcellulose-based injection moulded matrix tablets: in vitro and in vivo evaluation.
De Beer, T; Mendez-Montealvo, G; Onofre, FO; Quinten, T; Remon, JP; Vervaet, C; Wang, YJ, 2011
)
0.37
"The objective of the present study was to enhance solubility and bioavailability of itraconazole by a combined use of membrane emulsification and spray drying solidification technique."( Enhanced solubility and oral bioavailability of itraconazole by combining membrane emulsification and spray drying technique.
Choi, HG; Choi, YK; Kim, JO; Kim, JW; Marasini, N; Poudel, BK; Yang, KY; Yong, CS, 2012
)
0.38
" In both types of PSA, a constant absorption rate was maintained for up to 23 h after 7-h lag time."( In vivo enhancement of transdermal absorption of ketotifen by supersaturation generated by amorphous form of the drug.
Inoue, K; Sugibayashi, K, 2012
)
0.38
"The solubility, absorption and distribution of a drug are involved in the basic aspects of oral bioavailability Solubility is an essential characteristic and influences the efficiency of the drug."( Preparation of candesartan and atorvastatin nanoparticles by solvent evaporation.
Dohnal, J; Grunwaldova, V; Jampilek, J; Kral, V; Vaculikova, E, 2012
)
0.38
" The physicochemical properties, drug release profile, and bioavailability of SD prepared by SW process were also compared to SD prepared by the conventional co-precipitation method."( Improved oral absorption and chemical stability of everolimus via preparation of solid dispersion using solvent wetting technique.
Jang, SW; Kang, MJ, 2014
)
0.4
" Results proved the superiority of the designed formulation over the market product Stuval® tablets in bioavailability parameters comprising T max as well as area under the plasma CIN concentration-time curve (AUC0-24 h) and AUC0-∞ values."( Design and optimization of gastro-retentive microballoons for enhanced bioavailability of cinnarizine.
Ammar, HO; Ghorab, M; Kamel, R; Salama, AH, 2016
)
0.43
"Currently, infections following cataract surgery are not as effectively managed with antibiotic eye drops, which suffer from poor bioavailability of drug and low patient compliance."( Sustained Antibiotic-Eluting Intra-Ocular Lenses: A New Approach.
Lim, SG; Tan, DW; Venkatraman, SS; Wong, TT, 2016
)
0.43

Dosage Studied

The presence of carboxyhemoglobin in non-smokers exposed to methylene chloride results primarily from the metabolism of methylene chlorine in the liver. A further group of rats and mice were dosed intravenously with [14C]formate after exposure to nonradiolabeledmethylene chloride for 3 hr to determine the pattern of labeling resulting from incorporation of formate into DNA.

ExcerptRelevanceReference
" Optimization of the KAS, KAD, and KT values for each dosing solution allowed accurate simulation of each data set."( Gastrointestinal absorption of xenobiotics in physiologically based pharmacokinetic models. A two-compartment description.
Connolly, RB; Fisher, JW; Staats, DA,
)
0.13
" A review of the use of metabolism and pharmacokinetics in risk assessment reveals how this type of data can explain species differences, the shape of the dose-response curve and even determine the relevance of the animal carcinogenicity data to man."( Species differences in carcinogenicity: the role of metabolism and pharmacokinetics in risk assessment.
Green, T, 1991
)
0.28
"The aim of this study was to investigate the reproducibility of carcinogenic potencies estimated by multistage model (and its linearized form) fitting to dose-response relationships referring to different rodent species and strains, different sexes, target organs and severity of prognosis."( Reproducibility of carcinogenic potencies estimated in different rodent species. Methylene chloride: a useful example.
Bucchi, AR; Loizzo, A; Zapponi, GA, 1990
)
0.51
" The route of exposure and the composition of the dosing solution were found to have a significant effect on the pharmacokinetics."( The pharmacokinetics of dichloromethane. I. Disposition in B6C3F1 mice following intravenous and oral administration.
Angelo, MJ; Hawkins, DR; Pritchard, AB; Roberts, A; Waller, AR, 1986
)
0.27
" A further group of rats and mice were dosed intravenously with [14C]formate after exposure to nonradiolabeled methylene chloride for 3 hr to determine the pattern of labeling resulting from incorporation of formate into DNA via the C-1 pool."( Macromolecular interactions of inhaled methylene chloride in rats and mice.
Collinge, DC; Green, T; Guest, AE; Provan, WM, 1988
)
0.76
"1); dose-response relationships based on career methylene chloride exposure and latency were not demonstrated."( Methylene chloride mortality study: dose-response characterization and animal model comparison.
Friedlander, BR; Grose, F; Hearne, FT; Pifer, JW; Raleigh, RL, 1987
)
1.97
" This study was done to determine if Balbc/3T3 cells exposed to extracts of air samples could, unlike their normal counterparts, in the absence of a surface for attachment, divide on agar to form aggregates, and if these cells would demonstrate a dose-response phenomenon."( Balbc/3T3 cell transformation response to extracts of organic air samples as seen by their survival in aggregate form.
Daisey, JM; Kneip, TJ; Traul, KA; Zelikoff, JT, 1985
)
0.27
" Through computer simulations, how different dosing variables, such as dose vehicle and exposure route, could influence the time course of methylene chloride concentrations at potentially critical sites of toxicity was examined."( Simulations of methylene chloride pharmacokinetics using a physiologically based model.
Angelo, MJ; Pritchard, AB, 1984
)
0.82
" The serum concentrations-time curve over the first 8 hr after intravenous dosing appears biexponential with the disposition phase having a harmonic mean half-life (t 1/2) of 2 hr."( Clodronate kinetics and bioavailability.
Ampulski, RS; Benedict, JJ; Floyd, BF; Poynor, WJ; Slough, CL; Talbert, RL; Yakatan, GJ, 1982
)
0.26
" Human dose-response data, tolerance levels, and the effects of physical exercise and smoking on DCM toxicity are reported."( Safety standards for occupational exposure to dichloromethane.
Babish, JG; Skrabalak, DS, 1983
)
0.27
" We present simple methods for combining dose information from the study of interest with dose-response data from other epidemiologic studies or animal studies to derive plausible hypothesized effect levels."( Resolving discrepancies among studies: the influence of dose on effect size.
Hertz-Picciotto, I; Neutra, RR, 1994
)
0.29
" The capability of predicting the target tissue exposure to toxic moiety in people with PBPK models should help reduce the uncertainty associated with the extrapolation procedures adopted in conventional dose-response assessment."( Physiologically based pharmacokinetics and cancer risk assessment.
Andersen, ME; Krishnan, K, 1994
)
0.29
" Loss of body weight during the dosing period, ranging from slight to severe was seen in the treated animals."( Pregnancy terminating effect of Jatropha curcas in rats.
Balasubramaniam, S; Goonasekera, MM; Gunawardana, VK; Jayasena, K; Mohammed, SG, 1995
)
0.29
" A dose-response effect was seen only in the nonsmoking group."( Carboxyhemoglobin levels in methylene chloride-exposed employees.
Amsel, J; Marras, G; Soden, KJ, 1996
)
0.59
" Testing times after dosing varied among compounds and were based on pilot studies to measure both the times of peak effect and recovery."( A comparison of the acute neuroactive effects of dichloromethane, 1,3-dichloropropane, and 1,2-dichlorobenzene on rat flash evoked potentials (FEPs).
Boyes, WK; Herr, DW, 1997
)
0.3
" The studies reported here attempt to continue in the spirit of the new RfC guidelines by incorporating both mechanistic and delivered dose information using a physiologically based pharmacokinetic (PBPK) model, along with quantitative dose-response information using the benchmark dose (BMD) method, into the noncancer risk assessment paradigm."( Investigation of the potential impact of benchmark dose and pharmacokinetic modeling in noncancer risk assessment.
Clewell, HJ; Gearhart, JM; Gentry, PR, 1997
)
0.3
"The presence of carboxyhemoglobin in non-smokers exposed to methylene chloride results primarily from the metabolism of methylene chloride in the liver and exhibits a linear dose-response relationship."( Observed versus predicted carboxyhemoglobin levels in cellulose triacetate workers exposed to methylene chloride.
Amsel, J; Sielken, RL; Soden, KJ; Valdez-Flora, C, 2001
)
0.77
"Protein inactivation and aggregation at the water/CH2Cl2 interface is one of the most detrimental events hindering the encapsulation of structurally unperturbed proteins into poly(lactide-co-glycolide) (PLG) microspheres for their clinical application as sustained release dosage forms."( Improved activity and stability of lysozyme at the water/CH2Cl2 interface: enzyme unfolding and aggregation and its prevention by polyols.
Griebenow, K; Pérez, C, 2001
)
0.31
"Experience with dose response and mechanisms of toxicity has shown that multiple mechanisms may exist for a single agent along the continuum of the full dose-response curve."( Dose-dependent transitions in mechanisms of toxicity: case studies.
Andersen, ME; Bogdanffy, MS; Bus, JS; Cohen, SD; Conolly, RB; David, RM; Doerrer, NG; Dorman, DC; Gaylor, DW; Hattis, D; Rogers, JM; Setzer, RW; Slikker, W; Swenberg, JA; Wallace, K, 2004
)
0.32
" Therefore, Bayesian analysis of the mouse PBPK model and dose-response modeling was undertaken to support development of an improved cancer risk assessment for DCM."( Revised assessment of cancer risk to dichloromethane: part I Bayesian PBPK and dose-response modeling in mice.
Clewell, HJ; Covington, TR; David, RM; Gentry, PR; Hack, CE; Marino, DJ; Morgott, DA, 2006
)
0.33
" Colchicine in pure form and in dosage form was applied in this study."( Spectroscopic studies of charge transfer complexes between colchicine and some pi acceptors.
Arslan, M; Duymus, H, 2007
)
0.34
"A revised assessment of dichloromethane (DCM) has recently been reported that examines the influence of human genetic polymorphisms on cancer risks using deterministic PBPK and dose-response modeling in the mouse combined with probabilistic PBPK modeling in humans."( Probabilistic dose-response modeling: case study using dichloromethane PBPK model results.
Marino, DJ; Starr, TB, 2007
)
0.34
" The proposed methods have been applied successfully for the analysis of the drug in its dosage forms."( Extractive spectrophotometric methods for determination of zolmitriptan in tablets.
Aydogmus, Z; Inanli, I,
)
0.13
" Low residues and short half-life in corn suggested that nicosulfuron could be safely used in corn crops with the suitable dosage and application."( Dissipation and residues of nicosulfuron in corn and soil under field conditions.
Chen, X; Han, L; Wu, Q; Xu, Y, 2010
)
0.36
"The objective of this investigation was to develop the hollow microspheres as a new dosage form of floating drug delivery system with prolonged stomach retention time."( Preparation of Eudragit E100 microspheres by modified solvent evaporation method.
Chaudhary, AK; Singh, V,
)
0.13
" The single-factor experiments were adopted to investigate the effects of five independent variables (including material/liquid ratio, distillation time, dosage of NaCl, volume of CH(2)Cl(2) and water-bath temperature) on the extraction of aroma components in tobacco."( Optimization extraction process of aroma components in tobacco.
Chang, S; Cheng, H; Dong, S; Du, W; Luo, H; Wang, C; Wang, S; Xu, C; Zhang, J, 2013
)
0.39
" Quality by design (QbD) concept was implemented for the development of MDDC with potential to be incorporated into semisolid dosage form (gel)."( Implementation of quality by design principles in the development of microsponges as drug delivery carriers: Identification and optimization of critical factors using multivariate statistical analyses and design of experiments studies.
Dimitrovska, A; Glavas Dodov, M; Mladenovska, K; Sibinovska, N; Simonoska Crcarevska, M; Slavevska Raicki, R, 2015
)
0.42
" Also, the significantly greater value of mean residence time (MRT) in case of MB-F21 indicates its higher gastric residence time and proves the advantages of micro-multiparticulate dosage forms over conventional one."( Design and optimization of gastro-retentive microballoons for enhanced bioavailability of cinnarizine.
Ammar, HO; Ghorab, M; Kamel, R; Salama, AH, 2016
)
0.43
"The present research project involves development and validation of a stability-indicating HPTLC method for the estimation of naratriptan-HCl in their pharmaceutical dosage forms and its content uniformity testing."( Development and Validation of Stability-Indicating HPTLC Method for Estimation of Naratriptan Hydrochloride in Its Pharmaceutical Dosage Form and Its Content Uniformity Testing.
Bodiwala, KB; Chotalia, J; Marolia, BP; Prajapati, PB; Shah, SA, 2016
)
0.43
"51) among men in an analysis with 5 years lag-time, though without dose-response pattern."( Occupational solvent exposure and adult chronic lymphocytic leukemia: No risk in a population-based case-control study in four Nordic countries.
Auvinen, A; Hansen, J; Kjaerheim, K; Martinsen, JI; Pukkala, E; Talibov, M; Tryggvadottir, L; Weiderpass, E, 2017
)
0.46
"We review approaches for characterizing "peak" exposures in epidemiologic studies and methods for incorporating peak exposure metrics in dose-response assessments that contribute to risk assessment."( Peak Exposures in Epidemiologic Studies and Cancer Risks: Considerations for Regulatory Risk Assessment.
Checkoway, H; Dell, LD; Gentry, PR; Lees, PSJ; Mundt, KA, 2019
)
0.51
" Finally, in the third and fourth steps, different concentrations of chitosan (CN) and constant dosage of Melilotus officinalis (MO) extract were added to the solution."( Step-by-step design of poly (ε-caprolactone) /chitosan/Melilotus officinalis extract electrospun nanofibers for wound dressing applications.
Haddadi-Asl, V; Shahrousvand, M, 2021
)
0.62
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
polar aprotic solventA solvent with a comparatively high relative permittivity (or dielectric constant), greater than ca. 15, and a sizable permanent dipole moment, that cannot donate suitably labile hydrogen atoms to form strong hydrogen bonds.
carcinogenic agentA role played by a chemical compound which is known to induce a process of carcinogenesis by corrupting normal cellular pathways, leading to the acquistion of tumoral capabilities.
refrigerantA substance used in a thermodynamic heat pump cycle or refrigeration cycle that undergoes a phase change from a gas to a liquid and back. Refrigerants are used in air-conditioning systems and freezers or refrigerators and are assigned a "R" number (by ASHRAE - formerly the American Society of Heating, Refrigerating and Air Conditioning Engineers), which is determined systematically according to their molecular structure.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
chloromethanesA halomethane that is methane in which one or more hydrogens has been replaced by chlorine.
volatile organic compoundAny organic compound having an initial boiling point less than or equal to 250 degreeC (482 degreeF) measured at a standard atmospheric pressure of 101.3 kPa.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (3)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency39.81070.011212.4002100.0000AID1030
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency60.19930.001530.607315,848.9004AID1224841
activating transcription factor 6Homo sapiens (human)Potency24.18140.143427.612159.8106AID1159516
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (11)

Assay IDTitleYearJournalArticle
AID19825Partition coefficient (logP)1995Journal of medicinal chemistry, Feb-17, Volume: 38, Issue:4
Molecular similarity matrices and quantitative structure-activity relationships: a case study with methodological implications.
AID433903Hepatotoxicity in mouse assessed as carcinogenic potency2009European journal of medicinal chemistry, Sep, Volume: 44, Issue:9
Development of QSAR models for predicting hepatocarcinogenic toxicity of chemicals.
AID37562Induction of aneuploidy in Aspergillus nidulans.1995Journal of medicinal chemistry, Feb-17, Volume: 38, Issue:4
Molecular similarity matrices and quantitative structure-activity relationships: a case study with methodological implications.
AID1682590Cytotoxicity against human HL-60 cells assessed as reduction in cell viability incubated for 48 hrs by CCK-8 assay2021Bioorganic & medicinal chemistry letters, 01-01, Volume: 31Cytotoxic components from the leaves of Erythrophleum fordii induce human acute leukemia cell apoptosis through caspase 3 activation and PARP cleavage.
AID603950In-vitro air to lung partition coefficients of the compound, logK(lung) (human/rat)2008European journal of medicinal chemistry, Mar, Volume: 43, Issue:3
Air to lung partition coefficients for volatile organic compounds and blood to lung partition coefficients for volatile organic compounds and drugs.
AID422398Antitrypanosomal activity against Trypanosoma brucei2009Journal of natural products, Feb-27, Volume: 72, Issue:2
The marine sponge Diacarnus bismarckensis as a source of peroxiterpene inhibitors of Trypanosoma brucei, the causative agent of sleeping sickness.
AID162229Toxicity determined using Konemann's Industrial Pollutants Toxicity Test1991Journal of medicinal chemistry, May, Volume: 34, Issue:5
Using theoretical descriptors in quantitative structure-activity relationships: some toxicological indices.
AID23443Partition coefficient (logP)1985Journal of medicinal chemistry, Mar, Volume: 28, Issue:3
Use of physicochemical parameters in distance geometry and related three-dimensional quantitative structure-activity relationships: a demonstration using Escherichia coli dihydrofolate reductase inhibitors.
AID603952In-vitro blood to lung partition coefficients of the compound, logP(lung) (human/rat)2008European journal of medicinal chemistry, Mar, Volume: 43, Issue:3
Air to lung partition coefficients for volatile organic compounds and blood to lung partition coefficients for volatile organic compounds and drugs.
AID1682589Cytotoxicity against human KG-1 cells assessed as reduction in cell viability incubated for 48 hrs by CCK-8 assay2021Bioorganic & medicinal chemistry letters, 01-01, Volume: 31Cytotoxic components from the leaves of Erythrophleum fordii induce human acute leukemia cell apoptosis through caspase 3 activation and PARP cleavage.
AID603951In-vitro air to blood partition coefficients of the compound, logK(blood) (human/rat)2008European journal of medicinal chemistry, Mar, Volume: 43, Issue:3
Air to lung partition coefficients for volatile organic compounds and blood to lung partition coefficients for volatile organic compounds and drugs.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,896)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990322 (16.98)18.7374
1990's325 (17.14)18.2507
2000's538 (28.38)29.6817
2010's559 (29.48)24.3611
2020's152 (8.02)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 54.71

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index54.71 (24.57)
Research Supply Index7.63 (2.92)
Research Growth Index4.67 (4.65)
Search Engine Demand Index137.37 (26.88)
Search Engine Supply Index2.91 (0.95)

This Compound (54.71)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials10 (0.49%)5.53%
Reviews59 (2.89%)6.00%
Case Studies74 (3.63%)4.05%
Observational0 (0.00%)0.25%
Other1,898 (92.99%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]